Theratechnologies Announces Commercialization Agreement for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theratechnologies Announces Commercialization Agreement for Tesamorelin in South Korea

MONTREAL, CANADA--(Marketwired - Aug. 31, 2015) - Theratechnologies Inc. (TSX:TH) is pleased to announce that it has concluded an agreement with BL&H Co., LTD (BL&H) for the distribution and commercialization of EGRIFTA ™ (tesamorelin for injection) for the treatment of HIV-associated lipodystrophy in South Korea.

Under the terms of this agreement, BL&H will be responsible to conduct all regulatory activities required to obtain marketing approval for EGRIFTA™ in South Korea. Until then, BL&H intends to distribute EGRIFTA™ in the territory through Named Patient Sales Programs.

Theratechnologies will manufacture and supply EGRIFTA ™ to BL&H at a predetermined transfer price. The agreement has a 10-year term.

"We are thrilled of our association with BL&H which has a fast growing portfolio of specialty products in South Korea. This agreement gives us a great opportunity to enter a new market over a short time frame. One objective of our 2015 business plan is finding partners to distribute EGRIFTA ™ in additional territories. Today's announcement brings us closer to achieving this goal and it represents another significant step towards bringing shareholder value through the realization of the full commercial potential of EGRIFTA ™ ," said Luc Tanguay, President and CEO, Theratechnologies Inc.

BL&H is a privately-owned company based in Seoul, South Korea. It is a leading distributor of pharmaceuticals and hospital-based products and services in South Korea.

About Theratechnologies

Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs in metabolic disorders to promote healthy ageing and an improved quality of life. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com

Forward-Looking Information

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management's belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as "may", "will", "should", "could", "would", "outlook", "believe", "plan", "envisage", "anticipate", "expect" and "estimate", or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the distribution of EGRIFTA ™ through Named Patients Sales Programs, marketing approval of EGRIFTA ™ in South Korea and our capacity to ensure a reliable source of supply of EGRIFTA ™ .

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include, but are not limited to, the following: BL&H will be successful in distributing EGRIFTA ™ through Named Patients Sales Programs, EGRIFTA ™ will receive regulatory approval in South Korea, no additional clinical studies will be required by the regulatory authorities in South Korea to obtain these regulatory approvals, EGRIFTA ™ will be accepted by healthcare professionals, patients and third-party payors in South Korea, the relationships with our third-party suppliers will be conflict-free and we will have a continuous supply of EGRIFTA ™ .

These risks and uncertainties include, but are not limited to, the risk that regulatory changes prevent BL&H from distributing EGRIFTA ™ through Named Patient Sales Programs, EGRIFTA ™ is not approved in South Korea, market recall or market withdrawal of EGRIFTA ™ occurs in the countries where EGRIFTA ™ is commercialized, additional clinical data are required as a condition to approving EGRIFTA ™ and manufacturing issues prevent us from supplying EGRIFTA ™ to BL&H.

We refer potential investors to the "Risk Factors" section of our Annual Information Form dated February 25, 2015 available at www.sedar.com for additional risks regarding the Company and its operation. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date.

We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

Denis Boucher 514-913-1957
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 19

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 21

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 74

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 50

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 31

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 49

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 101

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 217

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading

Top 5 Most Recently Viewed Articles

commercetools Compilations: Innovations Driving Digital Growth

Updated Category News Views 177

Exciting Launch of commercetools Compilations commercetools has unveiled Compilations, a semi-annual showcase that highlights more than 50 product enhancements, demonstrating the organization’s dedication to innovation and improved customer experiences for users of the commercetools Platform. With over 13,000 deployments and 200 releases, this initiative significantly...

Continue Reading
Join the Class Action Against Red Cat Holdings, Inc. Today

Updated Category News Views 185

Understanding the Class Action Against Red Cat Holdings, Inc. Red Cat Holdings, Inc. is currently under the spotlight due to a class action securities lawsuit filed by the law firm Levi & Korsinsky, LLP. The firm is reaching out to investors who believe they have incurred losses due to the alleged securities fraud that transpired between a specified period. If you have...

Continue Reading
GRAIL Initiates Patient Testing with Innovative Blood Test for Lung Cancer

Updated Category News Views 127

GRAIL Announces Milestone in Lung Cancer Detection GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare firm focused on early cancer detection, has achieved a significant milestone by announcing that the first patient has been assessed for eligibility through its innovative non-small cell lung cancer (NSCLC) ctDNA Assay. This groundbreaking development occurs within the...

Continue Reading
Neurocrine Biosciences Enhances Collaboration with Takeda

Updated Category News Views 197

Neurocrine Biosciences Enhances Collaboration with Takeda Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has recently announced an amendment to strengthen the strategic collaboration with Takeda. This partnership focuses on the development and commercialization of osavampator, an innovative therapeutic candidate that holds promise for patients suffering from major depressive...

Continue Reading
LivaNova Prepares to Reveal 2024 Year-End Financials

Updated Category News Views 94

LivaNova's Upcoming Financial Announcement LivaNova PLC (Nasdaq: LIVN), a prominent player in the medical technology sector, is gearing up for an important event. The company will hold a conference call in which they will discuss their financial results from the fourth quarter as well as the entire year of 2024. This event is slated for a Tuesday afternoon and is expected...

Continue Reading